Piramal Pharma’s stock fell 2% after the company reported a 63.4% year-on-year fall in net profit in the third quarter of fiscal year 25. The firm reported a net profit of ₹3.7 crore, a decline from ₹10.1 crore in Q3 FY24. However, income from operations increased by 12.5% to ₹2,204.2 crore from ₹1,958.6 crore in the same period last year.
EBITDA jumped 25.8% at the operating level, reaching ₹337.7 crore with an EBITDA margin of 15.3%, compared to 13.7% in Q3 of FY24. The net-debt-to-EBITDA ratio remained at 2.8x for the firm.
Piramal Pharma’s Contract Development and Manufacturing Organization (CDMO) business witnessed high-teen revenue growth, driven by on-patent commercial manufacturing and a strong performance in the generic API sector. The Complex Hospital Generics (CHG) segment also performed well, particularly in the US, with growth in inhalation anesthesia products like Sevoflurane and Isoflurane.
In the India Consumer Healthcare (ICH) segment, Power Brands such as Little’s, Polycrol, and CIR saw a 19% growth year-on-year. Despite the industry’s tepid demand, ICH delivered double-digit revenue growth.
Piramal Pharma’s stock opened at ₹204.20, reaching a high of ₹217.70 and a low of ₹204.20 during the trading session. The stock has seen a 52-week high of ₹307.85 and a 52-week low of ₹114.45, reflecting significant volatility. As of 10:14 AM, the shares were trading 2.12% lower at Rs 214.30.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
